General Info

Jan N. Basile, M.D. was the chief of primary care at the Ralph H. Johnson VA Medical Center from where he retired in 2009 after 31 years of service. He is currently professor of medicine in the division of Cardiology at MUSC. He received his undergraduate degree from Johns Hopkins University and his M.D. from the Medical College of Virginia in Richmond. He served his internship and residency at the Medical University of South Carolina in Charleston, where he was also chief resident. Dr. Basile is a fellow of the American College of Physicians, the American Society of Hypertension, and the American Heart Association. He is board certified in internal medicine and has been designated as a specialist in clinical hypertension by the American Society of Hypertension.A recipient of many honors and awards, including the Excellence in Teaching Award and the Golden Apple Award at the Medical University of South Carolina School of Medicine, Dr. Basile's interests involve resistant hypertension ,His research interests include outcome-based clinical trials involving hypertension, lipid disorders and diabetes. He has been involved in several large studies evaluating the effect of pharmacologic therapy on improving patient outcome. These included the completed antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT), valsartan antihypertensive long-term use evaluation (VALUE) trial, avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) study,FALSE, as well as the ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET). He was involved in both the Action to Control Cardiovascular Risk in Diabetes (ACCORD) and the Systolic Prevention Intervention Trial (SPRINT). He was also a world wide coordinator and PI for the REWIND study with the GLP-1RA Dulaglutide. He continues to be involved in the RADIANCE II and Target I BP studies in Renal Denervation. as well as the ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET). He was involved in both the Action to Control Cardiovascular Risk in Diabetes (ACCORD) and the Systolic Prevention Intervention Trial (SPRINT). He was also a world wide coordinator and PI for the REWIND study with the GLP-1RA Dulaglutide.In addition to contributing to the 7th joint national committee report on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7),FALSE, Dr. Basile has contributed over 400 publications to the scientific literature including original articles, abstracts, and book chapters. He was senior editor of The Journal of Clinical Hypertension and co-author of a textbook: Hot Topics: Hypertension. Dr Basile was recently the recipient of the American Heart Association 2019 Marvin Moser Award in Clinical Hypertension. , Dr. Basile has contributed over 400 publications to the scientific literature including original articles, abstracts, and book chapters. He was senior editor of The Journal of Clinical Hypertension and co-author of a textbook: Hot Topics: Hypertension. Dr Basile only sees patient with resistant hypertension who are referred by their treating clinician and not self-referred for hypertension. If clinicians have questions on their patients they may reach him at any time at his MUSC email address. In addition to contributing to the 7th joint national committee report on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7), Dr. Basile has contributed over 400 publications to the scientific literature including original articles, abstracts, and book chapters. He was senior editor of The Journal of Clinical Hypertension and co-author of a textbook: Hot Topics: Hypertension.